Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research

Biochemical and Biophysical Research Communications

Volumn 405, Issue 1, 2011, Pages 85-90

  McNutt, Patrick ^a   Celver, Jeremy ^b   Hamilton, Tracey ^a   Mesngon, Mariano ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Botulinum neurotoxin; Embryonic stem cells; Embryonic stem cell derived neurons; In vitro neurotoxicology

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN E; CALCIUM; GLUTAMIC ACID; POTASSIUM; SNARE PROTEIN; SYNAPTOBREVIN 2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN;

ANIMAL CELL; ARTICLE; CELL LINE; CELL POPULATION; CONTROLLED STUDY; DEPOLARIZATION; EMBRYONIC STEM CELL; INTOXICATION; MOUSE; NERVE CELL; NEUROTOXICOLOGY; NONHUMAN; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SYNAPSE; TISSUE CULTURE;

ANIMALS; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; CALCIUM; EMBRYONIC STEM CELLS; EXOCYTOSIS; GLUTAMIC ACID; MICE; MODELS, BIOLOGICAL; NEUROGENESIS; NEURONS; PROTEIN BIOSYNTHESIS; SYNAPSES; TISSUE CULTURE TECHNIQUES;

ANIMALIA; MURINAE;

EID: 79551494442     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.132     Document Type: Article

References (27)

1. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44:167-193.
2. Larsen J.C. Army Botulinum Neurotoxin (BoNT) Medical Therapeutics Research Program: past accomplishments and future directions. Drug Dev. Res. 2009, 70:266-278.
3. Adler M., Keller J.E., Sheridan R.E., Deshpande S.S. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 2001, 39:233-243.
4. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., Smith L., Aoki K.R., Dolly J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 2003, 278:1363-1371.
5. Larsen J.C. Botulinum Neurotoxin (BoNT) therapeutics: time to think outside the BoNT? Botulinum J. 2009, 1:261-269.
6. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 1981, 33:155-188.
7. Stahl A.M., Ruthel G., Torres-Melendez E., Kenny T.A., Panchal R.G., Bavari S. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J. Biomol. Screen. 2007, 12:370-377.
8. Keller J.E., Neale E.A., Oyler G., Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999, 456:137-142.
9. Pellett S., Tepp W.H., Clancy C.M., Borodic G.E., Johnson E.A. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007, 581:4803-4808.
10. Purkiss J.R., Friis L.M., Doward S., Quinn C.P. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology 2001, 22:447-453.
11. Lawrence G.W., Foran P., Dolly J.O. Distinct exocytotic responses of intact and permeabilised chromaffin cells after cleavage of the 25-kDa synaptosomal-associated protein (SNAP-25) or synaptobrevin by botulinum toxin A or B. Eur. J. Biochem. 1996, 236:877-886.
12. Yowler B.C., Kensinger R.D., Schengrund C.L. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 2002, 277:32815-32819.
13. Lee J.-O., Rosenfield J., Tzipori S., Park J.-B. M17 human neuroblastoma cell as a cell model for investigation of Botulinum Neurotoxin A activity and evaluation of BoNT/A specific antibody. Botulinum J. 2008, 1:135-152.
14. Eubanks L.M., Hixon M.S., Jin W., Hong S., Clancy C.M., Tepp W.H., Baldwin M.R., Malizio C.J., Goodnough M.C., Barbieri J.T., Johnson E.A., Boger D.L., Dickerson T.J., Janda K.D. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. USA 2007, 104:2602-2607.
15. NIAID, Summary of the NIAID expert panel on Botulinum neurotoxins therapeutics, NIAID Expert Panel on Botulinum Neurotoxins Therapeutics, National Institute of Allergy and Infectious Diseases, Bethesda, MD, 2004.
16. Bibel M., Richter J., Schrenk K., Tucker K.L., Staiger V., Korte M., Goetz M., Barde Y.A. Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat. Neurosci. 2004, 7:1003-1009.
17. Bain G., Kitchens D., Yao M., Huettner J.E., Gottlieb D.I. Embryonic stem cells express neuronal properties in vitro. Dev. Biol. 1995, 168:342-357.
18. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108:193-199.
19. Koga T., Kozaki S., Takahashi M. Exocytotic release of alanine from cultured cerebellar neurons. Brain Res. 2002, 952:282-289.
20. Bibel M., Richter J., Lacroix E., Barde Y.A. Generation of a defined and uniform population of CNS progenitors and neurons from mouse embryonic stem cells. Nat. Protoc. 2007, 2:1034-1043.
21. Levi G., Raiteri M. Carrier-mediated release of neurotransmitters. Trends Neurosci. 1993, 16:415-419.
22. Shimamoto K., Lebrun B., Yasuda-Kamatani Y., Sakaitani M., Shigeri Y., Yumoto N., Nakajima T. DL-threo-beta-benzyloxyaspartate a potent blocker of excitatory amino acid transporters. Mol. Pharmacol. 1998, 53:195-201.
23. Sheridan R.E., Smith T.J., Adler M. Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon 2005, 45:377-382.
24. Keller J.E., Cai F., Neale E.A. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 2004, 43:526-532.
25. NIEHS, Report on the ICCVAM-NICEATM/ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce or Replace the Mouse LD50 Assay for Botulinum Toxin Testing, 2008.
26. Suter D.M., Cartier L., Bettiol E., Tirefort D., Jaconi M.E., Dubois-Dauphin M., Krause K.H. Rapid generation of stable transgenic embryonic stem cell lines using modular lentivectors. Stem Cells 2006, 24:615-623.
27. Adams L.D., Choi L., Xian H.Q., Yang A., Sauer B., Wei L., Gottlieb D.I. Double lox targeting for neural cell transgenesis. Brain Res. Mol. Brain Res. 2003, 110:220-233.